MARK N LAMPERT
CIK 1233840 · last filed 2023-11-06
MARK N LAMPERT is a corporate insider who has filed 42 SEC Form 4 insider transactions across 23 companies since 2009. The most recent filing shows the insider bought $53.0M of KYMR on Nov 6, 2023. Across all open-market trades the lifetime net is +$37.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.22B across reported positions. 360 SEC filings were submitted jointly with BVF INC/IL.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.22B
Companies
23
Total Filings
42
Lifetime Open-Market Net
$37.95M
Filer Profile
Reported Address
44 MONTGOMERY ST.40TH FLOOR
SAN FRANCISCO, CA 94104
Related Filers
BVF INC/IL — 360 joint filings, latest 2026-07-16
BVF PARTNERS L P/IL — 360 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND L P — 358 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND II LP — 354 joint filings, latest 2026-07-16
BVF Partners OS Ltd. — 237 joint filings, latest 2026-07-16
Biotechnology Value Trading Fund OS LP — 237 joint filings, latest 2026-07-16
BVF GP HOLDINGS LLC — 155 joint filings, latest 2026-07-16
BVF I GP LLC — 155 joint filings, latest 2026-07-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 2,552,306 | $114.96 | $293.41M | $53.01M | 1 | 2023-11-06 |
| OLMA | Director | 3,913,676 | $10.22 | $40.00M | $0 | 1 | 2023-06-21 |
| XOMA Royalty Corp (XOMAP) Delisted | Director | 1,989,844 | $24.98 | $49.71M | $4.21M | 1 | 2023-01-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 3,350,950 | $2.65 | $8.88M | $35.70M | 1 | 2022-05-20 |
| CGEM | 10%+ Owner | 2,196,240 | $20.59 | $45.22M | $29.67M | 1 | 2022-04-05 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 4,611,909 | $38.00 | $175.25M | $21.84M | 1 | 2020-11-06 |
| Principia Biopharma Inc. (PRNB) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2020-08-20 |
| Calithera Biosciences, Inc. (CALA) Delisted | 10%+ Owner | 185,617 | $0.00 | $56 | -$90.66M | 2 | 2020-05-26 |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 1,804,105 | $90.00 | $162.37M | $31.51M | 1 | 2020-01-21 |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 1,335,192 | $40.17 | $53.63M | $57.47M | 1 | 2019-12-20 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 5,289 | $15.70 | $83.0K | $37.17M | 1 | 2019-09-09 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,510,597 | $0.04 | $291.0K | $21.70M | 2 | 2018-11-30 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 10%+ Owner | 951,300 | $8.37 | $7.96M | -$239.32M | 1 | 2017-12-21 |
| CAPS | 10%+ Owner | 0 | $0.18 | $0 | -$1.06M | 5 | 2017-07-18 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 10%+ Owner | 277,314 | — | — | $1.03M | 2 | 2017-06-22 |
| XENE | 10%+ Owner | 1,018,197 | $58.65 | $59.72M | $10.27M | 2 | 2017-06-19 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 2,218,076 | — | — | $0 | 1 | 2016-06-27 |
| CCXI | 10%+ Owner | 2,671,577 | $12.32 | $32.91M | $40.29M | 4 | 2015-11-05 |
| RIGL | 10%+ Owner | 79,962 | $47.24 | $3.78M | $680.4K | 1 | 2013-06-11 |
| LGND | 10%+ Owner | 741,627 | $284.47 | $210.97M | $35.05M | 4 | 2012-11-19 |
| NBIX | 10%+ Owner | 8,847,147 | $156.22 | $1.38B | -$647.3K | 2 | 2011-10-14 |
| Astex Pharmaceuticals, Inc (SUPG) Delisted | 10%+ Owner | 11,270,798 | — | — | -$3.63M | 1 | 2010-04-21 |
| RPRX | 10%+ Owner | 2,577,026 | $58.61 | $151.04M | -$6.35M | 2 | 2009-09-16 |
Recent Filings
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-06 | KYMR | Buy (P) | +4,141,050 | $53.01M | EDGAR |
| 2023-06-21 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2023-01-09 | XOMA Royalty Corp (XOMAP) Delisted | Buy (P) | +222,490 | $4.21M | EDGAR |
| 2022-05-20 | Repare Therapeutics Inc. (RPTX) Delisted | Buy (P) | +4,200,000 | $35.70M | EDGAR |
| 2022-04-05 | CGEM | Buy (P) | +2,760,000 | $29.67M | EDGAR |
| 2020-11-06 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +4,465,620 | $21.84M | EDGAR |
| 2020-08-20 | Principia Biopharma Inc. (PRNB) Delisted | Buy (P) | — | $0 | EDGAR |
| 2020-05-26 | Calithera Biosciences, Inc. (CALA) Delisted | Sell (S) | −15,985,186 | -$95.91M | EDGAR |
| 2020-01-21 | Merus N.V. (MRUS) Delisted | Buy (P) | +1,951,110 | $31.51M | EDGAR |
| 2019-12-20 | XOMA Royalty Corp (XOMA) Delisted | Mixed | +5,918,241 | $130.20M | EDGAR |
Showing 1–10 of 42
Page 1 of 5
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.